Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

Episode metadata supplied by the publisher feed · Published Nov 8, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

0:00 11:53

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 11 minutes long.

When was this BiotechTV - News episode published?

This episode was published on November 8, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!